EEG as a translational biomarker and outcome measure in fragile X syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Translational Psychiatry"
DOI: 10.1038/s41398-022-01796-2
Abstract: Targeted treatments for fragile X syndrome (FXS) have frequently failed to show efficacy in clinical testing, despite success at the preclinical stages. This has highlighted the need for more effective translational outcome measures. EEG differences… read more here.
Keywords: fragile syndrome; translational biomarker; biomarker outcome; eeg translational ... See more keywords